Shattuck Labs Inc (STTK) USD0.0001
1.26%- This stock can be held in a
Stocks and Shares ISA
$0.04
(4.95%)$0.04
(4.95%)Company Information
About this company
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Key people
Key facts
- EPICSTTK
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS82024L1035
- Market cap$40.78m
- Employees44
- Shares in issue47.90m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.